Balyasny Asset Management
IMVT icon

Balyasny Asset Management’s Immunovant IMVT Stock Holding History

Balyasny Asset Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-448,051
Closed -$7.22M – 3306
2025
Q3 		$7.22M Buy
448,051
+250,482
+127% +$4.06M 0.01% 1205
2025
Q2 		$3.16M Buy
+197,569
New +$2.99M ﹤0.01% 1513
2024
Q1 		– Sell
-9,783
Closed -$412K – 2845
2023
Q4 		$412K Buy
+9,783
New +$360K ﹤0.01% 2026
2023
Q3 		– Sell
-255,677
Closed -$5.78M – 2483
2023
Q2 		$4.85M Buy
+255,677
New +$4.77M 0.01% 1076
2023
Q1 		– Sell
-375,775
Closed -$6.67M – 2890
2022
Q4 		$6.67M Buy
375,775
+222,272
+145% +$2.8M 0.02% 906
2022
Q3 		$857K Buy
+153,503
New +$750K ﹤0.01% 1865
2022
Q2 		– Sell
-14,616
Closed -$81K – 2945
2022
Q1 		$81K Buy
+14,616
New +$91K ﹤0.01% 2172
2021
Q1 		– Sell
-59,974
Closed -$2.77M – 1908
2020
Q4 		$2.77M Buy
+59,974
New +$2.77M 0.02% 801

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Balyasny Asset Management's IMVT Position: Q4 2025 in Review

Balyasny Asset Management sold out of Immunovant (IMVT) in Q4 2025, closing a stake of 448,051 shares — an estimated $7.22M sold.

Balyasny Asset Management first reported a position in IMVT in Q4 2020 and held it in 8 quarters. The position peaked at $7.22M in Q3 2025. 196 funds tracked by Wall St. Rank hold IMVT as of Q4 2025.

  • Balyasny Asset Management reported no remaining Immunovant position as of Q4 2025 after selling out during the quarter.
  • Balyasny Asset Management sold 448,051 Immunovant shares in Q4 2025, an estimated $7.22M.
  • Balyasny Asset Management first reported a position in Immunovant in Q4 2020 and held it in 8 quarters.
  • Balyasny Asset Management's Immunovant position peaked at $7.22M in Q3 2025.
  • 196 funds tracked by Wall St. Rank held Immunovant as of Q4 2025.

Based on Balyasny Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.